NetworkNewsBreaks – CytoDyn Inc. (CYDY) Interim CMO to Present at 11th Annual Conference on Stem Cell and Regenerative Medicine

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning announced that Richard G. Pestell, M.D., Ph.D., president of the Pennsylvania Cancer and Regenerative Medicine Research Center, distinguished professor at the Baruch S. Blumberg Institute and interim chief medical officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine in Helsinki, Finland. Pestell’s presentation, titled ‘Cancer stem cells, genetic drivers and therapeutic targeting via CCR5’, is scheduled to take place on Monday, October 15, from 10-11 am EEST. Pestell will present recent scientific evidence demonstrating the effectiveness of PRO 140 (leronlimab), which is shown to bind to CCR5 in human breast cancer, block CCR5 signaling induced by cytokines and block human breast cancer cell invasion.

To view the full press release, visit http://nnw.fm/SgzM0

About CytoDyn

CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com

More from NetworkNewsBreaks

NetworkNewsBreaks – FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Adds Taxation Reporting Technology to its Proprietary Compliance Platform NetworkNewsBreaks – First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Announces Results of Independent Studies Supporting Restart of Canadian Refinery NetworkNewsBreaks – The Flowr Corporation (TSX.V: FLWR) Ships Initial Purchase Order from the NSLC

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.

Latest News

Genoa announces $229M project to replace collapsed bridge

Dec 19, 2018

MILAN — Genoa's mayor on Tuesday announced that a 202-million-euro ($229 million) project by hometown architect Renzo Piano inspired by a naval ship has been chosen to replace the Morandi Bridge that collapsed last summer, killing 43 people. The project will be carried out by three Italian firms, construction firm Salini Impregilo, state-run shipbuilder Fincantieri's infrastructure subsidiary and the Italferr state railway subsidiary, which will be charged with engineering aspects. Mayor Marco Bucci said construction will take 12 months and the bridge should be completed, although not yet accessible, by the end of 2019. The bridge will no longer carry...

Kosovo betrayed by EU on visa-free travel, premier says

Dec 19, 2018

BRUSSELS — Kosovo's prime minister said Monday the country feels betrayed by the European Union, which it is aspiring to join one day, because of the bloc's delays on enacting visa-free travel for its citizens. Ramush Haradinaj's comments came in a speech he made in Brussels at a meeting with senior EU officials. Kosovo's citizens "feel betrayed and disillusioned with the EU," he said. "Time is not our friend. We should see concrete progress." Haradinaj said that though Kosovo had fulfilled dozens of requirements set by EU members, the response from Brussels is "incomplete and hopeless." Kosovo is the only...

Prosecco's bubble shows no sign of bursting

Dec 19, 2018

ASOLO, Italy — Prosecco, the fruity sparkling wine made in the northeastern hills of Italy is gaining in global popularity — and producers of Champagne, for so long the dominant bubbly wine, are taking note. Prosecco has become the best-selling sparkling wine in the world by volume, and experts say it is eroding the market share of Champagne, the French wine that is synonymous with celebration but also comes with a heftier price tag. The Italian wine's production eclipsed Champagne's five years ago and is now 75 percent higher at 544 million bottles. Champagne still claims the revenues crown, cashing...

New Ukrainian Orthodox leader gives 1st liturgy, urges unity

Dec 19, 2018

MINSK, Belarus — In his first liturgy as head of the freshly christened Ukrainian Orthodox Church, Metropolitan Epiphanius called Sunday for Ukrainians to unite under the new church and pray for peace in Ukraine. Speaking the day after Ukrainian bishops approved the charter for a religious authority separate from the Russian Orthodox Church, Epiphanius appealed to Ukrainian priests who have worked under the Russian church to join his new community. "We are ready to accept them with brotherly love, mutual respect, and to forget all of the grievances that have accumulated so far," said Epiphanius, whom Ukraine's bishops elected Saturday...

Swiss ski team: No serious injury to Gisin's skull, spine

Dec 19, 2018

SELVA DI VAL GARDENA, Italy — The Swiss team says that "scans on the skull showed no serious injury" to Marc Gisin following his dramatic crash in a World Cup downhill but the skier does have several broken bones elsewhere on his body. A team statement Sunday says Gisin fractured several ribs on his right side, his right lung was also injured, his pelvis was dented slightly, plus he has a "few, non-serious fractures on the spine." Gisin will remain hospitalized in the intensive care unit at Lucerne Canton Hospital in Switzerland. The 30-year-old Gisin lost control before a jump...

Sign up now!

The Healthier Web delivers accurate and up-to-date health information through medical content and insights from experts. Feel the ‘ohm’ here in The Healthier Web.

Contact us: sales[at]thehealthierweb.com